Ikena Oncology, Inc.: management transactions · United States · SEC (Form 4)

About Ikena Oncology, Inc.

Ikena Oncology, Inc. was a United States-based biotechnology company listed on the Nasdaq market (NYSE/NASDAQ), with corporate operations centered in Boston, Massachusetts, United States. Historically, the company was positioned as a precision oncology developer focused on targeted therapies for biomarker-defined and genetically defined cancer subpopulations. Founded as a private biotech before going public in 2021, Ikena built its investment case around biology-driven programs aimed at signaling pathways that control tumor growth, spread, and therapeutic resistance. ([ir.ikenaoncology.com](https://ir.ikenaoncology.com/news-releases/news-release-details/ikena-oncology-announces-pricing-initial-public-offering/?utm_source=openai)) At the core of the company’s strategy was a clinical-stage pipeline featuring IK-930, a TEAD1-selective Hippo-pathway inhibitor, and IK-595, a MEK-RAF molecular glue designed to more fully suppress RAS signaling. Ikena also emphasized hard-to-treat oncology settings, particularly cancers driven by RAS/RAF alterations or Hippo-pathway dysregulation. That made the company a niche competitor in precision oncology: scientifically differentiated, but also highly dependent on clinical execution, regulatory progress, and access to capital. In practice, Ikena competed not only with other development-stage biotech names, but also indirectly with larger pharmaceutical groups that can move faster on trials, partnerships, or commercialization. ([ikenaoncology.com](https://ikenaoncology.com/pipeline/?utm_source=openai)) Geographically, Ikena operated primarily from Boston, leveraging the city’s deep biotechnology ecosystem for research, development, and corporate functions. As a U.S.-listed public company on Nasdaq, it relied heavily on equity markets and balance-sheet discipline to fund a pipeline that had not yet generated product revenue. SEC filings also reference Boston office, lab, and animal-care facilities, underscoring the company’s R&D-heavy footprint rather than a commercial manufacturing model. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1835579/000095017025034188/ikna-20241231.htm?utm_source=openai)) Recent corporate developments were material. In May 2024, Ikena announced it was discontinuing the clinical IK-930 program and concentrating resources on IK-595 while evaluating strategic alternatives to maximize shareholder value. That process ultimately culminated in a merger with Inmagene Biopharmaceuticals, completed on July 25, 2025. Following closing, Ikena Oncology changed its name to ImageneBio, Inc., and the shares began trading on Nasdaq under the new ticker IMA rather than IKNA. For investors analyzing historical Ikena filings, including SEC Form 4 insider transactions, this is an important context point: the legacy Ikena entity underwent a major strategic and corporate transformation in 2025. ([ir.ikenaoncology.com](https://ir.ikenaoncology.com/news-releases/news-release-details/update-ikena-oncology-announces-strategic-update?utm_source=openai))